This content is machine translated Multiple myeloma DREAMM-7: Belamaf plus bortezomib and dexamethasone outperforms comparator therapy In patients with multiple myeloma, the disease is often refractory to first-line triple or quadruple therapies. The result: a relapse occurs. Therefore, effective second-line therapy combinations are needed that include...…
View Post 11 min This content is machine translated Metastatic renal cell carcinoma (mRCC) Individual therapy management improves treatment success Increasing understanding of the pathogenetic relationships of renal cell carcinoma has contributed to the development of new drugs. These specifically interfere with the VEGF, PDGF and mTOR signaling pathways. In…
